Needham & Company LLC Issues Positive Forecast for Hims & Hers Health (NYSE:HIMS) Stock Price

Hims & Hers Health (NYSE:HIMS) had its price objective upped by Needham & Company LLC from $35.00 to $42.00 in a research report issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s price target would indicate a potential upside of 32.03% from the company’s current price.

Other equities research analysts also recently issued reports about the stock. JPMorgan Chase & Co. decreased their target price on shares of Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Jefferies Financial Group set a $24.50 price target on Hims & Hers Health in a research note on Tuesday, May 12th. Bank of America boosted their price objective on Hims & Hers Health from $36.00 to $37.00 and gave the stock a “neutral” rating in a report on Thursday, July 9th. Weiss Ratings restated a “sell (d)” rating on shares of Hims & Hers Health in a report on Friday. Finally, BTIG Research reaffirmed a “neutral” rating on shares of Hims & Hers Health in a research report on Tuesday, May 12th. Four research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $31.90.

Hims & Hers Health Trading Up 0.7%

Shares of Hims & Hers Health stock opened at $31.81 on Tuesday. The stock has a market capitalization of $7.36 billion, a PE ratio of -353.44, a price-to-earnings-growth ratio of 88.90 and a beta of 2.40. Hims & Hers Health has a 52 week low of $13.74 and a 52 week high of $65.30. The stock has a 50 day moving average price of $31.94 and a two-hundred day moving average price of $26.07. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The firm had revenue of $608.10 million during the quarter, compared to the consensus estimate of $616.84 million. During the same quarter in the prior year, the business earned $0.20 earnings per share. Hims & Hers Health’s revenue for the quarter was up 3.8% on a year-over-year basis. As a group, equities analysts anticipate that Hims & Hers Health will post 0.03 earnings per share for the current fiscal year.

Insider Activity at Hims & Hers Health

In other news, CFO Oluyemi Okupe sold 7,163 shares of the business’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $36.49, for a total value of $261,377.87. Following the sale, the chief financial officer owned 284,321 shares of the company’s stock, valued at $10,374,873.29. The trade was a 2.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David B. Wells acquired 48,400 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The stock was acquired at an average cost of $24.23 per share, with a total value of $1,172,732.00. Following the completion of the acquisition, the director owned 224,417 shares in the company, valued at $5,437,623.91. This trade represents a 27.50% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders sold 83,126 shares of company stock worth $2,711,339. 11.76% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in HIMS. Versant Capital Management Inc lifted its holdings in shares of Hims & Hers Health by 801.2% in the second quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock worth $26,000 after buying an additional 665 shares in the last quarter. MassMutual Private Wealth & Trust FSB boosted its holdings in Hims & Hers Health by 70.0% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock valued at $27,000 after purchasing an additional 319 shares during the period. Flagship Harbor Advisors LLC purchased a new position in shares of Hims & Hers Health during the 4th quarter valued at $28,000. Binnacle Investments Inc purchased a new position in shares of Hims & Hers Health during the 3rd quarter valued at $28,000. Finally, Bogart Wealth LLC increased its holdings in shares of Hims & Hers Health by 235.8% in the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after purchasing an additional 632 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Second-quarter revenue rose 38.2% year over year to approximately $753.2 million, exceeding the roughly $698.9 million analyst consensus. The company also cited strong subscriber growth and broader personalized healthcare offerings. Hims & Hers raises annual forecast revenue on strong subscriber growth
• Positive Sentiment: Hims & Hers raised its 2026 revenue forecast to $3.1 billion-$3.3 billion from $2.8 billion-$3.0 billion. Third-quarter revenue guidance of $880 million-$900 million also exceeds the approximately $845.9 million consensus estimate, signaling continued demand. Hims & Hers Boosts Revenue Target, Swings to Second-Quarter Loss
• Neutral Sentiment: Investor attention is focused on the company’s investment cycle, particularly its branded GLP-1 offering and international expansion. These initiatives could support long-term growth but may pressure near-term margins and earnings.
• Negative Sentiment: The company reported a second-quarter loss of $0.37 per share, far worse than the approximately $0.05 loss expected by analysts and sharply below the $0.17 profit reported a year earlier. The earnings miss overshadowed the revenue beat and higher forecast. Hims & Hers stock drops despite higher guidance
• Negative Sentiment: Several law firms announced investigations into potential securities-law or fiduciary-duty violations involving Hims & Hers directors and officers. The investigations are allegations rather than established findings, but they add reputational and legal uncertainty. Hims & Hers investor alert

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.